Second Genome

Second Genome is discovering and developing transformational precision therapies.

[Second Genome @SecondGenome]

Don’t miss President & CEO at Second Genome, Karim Dabbagh, at this week’s Precision Medicine World Conference - June 30 at 9:30am. Karim will be discussing microbiome pharma #DrugDevelopment with other R&D Leaders. #PMWC22 #PrecisionMedicine. Learn more: https://t.co/dXTLPHQFyC

[Second Genome @SecondGenome]

Karim Dabbagh, PhD, President & CEO of Second Genome is speaking at the Precision Medicine World Conference on June 30. Karim is joined by other R&D Leaders in Microbiome #DrugDevelopment during his session. Learn more about #PMWC22: https://t.co/Bd0AdY950m #PrecisionMedicine

[Second Genome @SecondGenome]

At #DDW2022, we presented new data from our #IBD program. Our PAI-1/2 modulator demonstrated improvement in epithelial barrier function and promotes mucosal healing. Read more: https://t.co/vJ5GMVO2If

[Second Genome @SecondGenome]

At #DDW2022, we presented data from our proprietary technology-enabled platform that identified immunomodulatory peptides with therapeutic potential. Read more: https://t.co/urGL7Cgqyl

[Second Genome @SecondGenome]

Second Genome recognizes World IBD Day in bringing awareness to challenges elderly living with Crohn’s/Ulcerative Colitis face. We understand the challenges faced by people living with #IBD and remain committed to advancing our research. #worldibdday2022 #IBDhasnoage

[Second Genome @SecondGenome]

Second Genome is a proud Program Sponsor at the #SITCWorkshop this week. Our preclinical data from our #oncology program, a potential novel #cancerimmunotherapy, was selected as an encore presentation. Learn more: https://t.co/SlHDCv6tbj

[Second Genome @SecondGenome]

At #AACR22, we presented new data from our #immunooncology program. Our novel CXCR3 chemokine receptor modulator demonstrated induction of immune effector cell migration, tumor growth inhibition and boosted anti-PD1 activity. Read more: https://t.co/Z1xxnEMWSt

[Second Genome @SecondGenome]

We are excited to announce Bayer exercised an option following the completion of our multi-year protein discovery collaboration. Read more about our work: https://t.co/rVR2UB1YGP

[Second Genome @SecondGenome]

Earlier this week, we hosted a virtual event featuring leading #IBD experts and Second Genome management. View the archived webcast to learn more: https://t.co/wWJdfRcd7D

[Second Genome @SecondGenome]

Thanks to everyone who tuned into our KOL event yesterday which focused on the role of #mucosalhealing and the need for new treatment strategies for #IBD, including our development candidate, SG-5-00455. Read the recap and get the on-demand recording link: https://t.co/tzYdXlvJB1

[Second Genome @SecondGenome]

Following our #ECCO2022 presentation, join our virtual event today to hear from world-renowned #IBD experts at 12 p.m. EST. An overview of development candidate, SG-5-00455, and the role of #mucosalhealing and PAI-1/2 in IBD will be discussed. View here: https://t.co/vGcfEfOypd

[Second Genome @SecondGenome]

At #ECCO2022, our CSO Joseph Dal Porto, Ph.D., presented exciting preclinical data from our #IBD program on behalf of our team. SG-5-00455 demonstrates a novel mechanism of action to modulate PAI-1/2 and directly target mucosal healing. Read more: https://t.co/mESXZFSc83

[Second Genome @SecondGenome]

Attend our virtual KOL event! We will discuss exciting progress on our #IBD development candidate and hear from experts, Dr. Ryan Balfour Sartor and Dr. Silvio Danese, on the role of #mucosal healing and PAI-1/2 in IBD. Learn more and get the event link: https://t.co/niqx3EnTCa

[Second Genome @SecondGenome]

Exciting news: We announced SG-5-00455 as our development candidate targeting PAI-1/2 for the treatment of #IBD. This is an important step toward the development of potential new therapeutic options for patients. Read more: https://t.co/0Oj0Trd4GT

[Second Genome @SecondGenome]

This #WorldCancerDay, we recognize the patients and their families who are facing #cancer, and the importance of innovating to overcome treatment challenges. We are proud to be advancing our lead #oncology program to improve therapy options. Learn more: https://t.co/OCHaLodtV2

[Second Genome @SecondGenome]

Thanks to @statnews for the feature on our new Chief Scientific Officer, Joseph Dal Porto! He had the opportunity to share an enjoyable hobby (coaching soccer) and what piece of lab equipment he would be (a mibi). Read more: https://t.co/awAltCFkPQ (subscription required)

[Second Genome @SecondGenome]

Our lead mucosal healing program drug candidate improved barrier function in preclinical #IBD models, showing potential to overcome limitations with current therapies. Learn about the data Chip La Chat presented at the @CrohnsColitisFn’s #CCCongress22: https://t.co/WeqQXnW2jL

[Second Genome @SecondGenome]

We are pleased to welcome Joseph Dal Porto, Ph.D., as Second Genome’s Chief Scientific Officer! With 20+ years of #drugdevelopment experience, he will lead our teams as we advance our #oncology, mucosal healing and other therapeutics programs. Learn more: https://t.co/CzcQOr7Sfy

[Second Genome @SecondGenome]

Over the past year, we have made exciting progress on our #mucosalhealing and #oncology programs and expanded our #biopharma collaborations leveraging our sg-4sight platform. We look forward to presenting these updates at the #BiotechShowcase beginning today.

[Second Genome @SecondGenome]

We are excited to announce we have received a U.S. patent for our lead mucosal healing program candidate in #IBD, which has potential application in a breadth of gastrointestinal disorders. Read more: https://t.co/MbmPsfOjo3